Artículos por temáticas

Fyn, a potential target for Alzheimer's disease

Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF.

J Alzheimers Dis. 2011;27(2):243-52. doi: 10.3233/JAD-2011-110353.

Risk-takers wanted

Nat Med. 2011 Nov 7;17(11):1321. doi: 10.1038/nm.2573.

Epigenetic treatment of neurological disease

Gray SG.

Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67.

The three stages of Alzheimer's disease

Lancet. 2011 Apr 30;377(9776):1465. doi: 10.1016/S0140-6736(11)60582-5.

[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease]

Delrieu J, Piau A, Vellas B.

Rev Med Interne. 2011 Jun;32 Suppl 1:S22-5. doi: 10.1016/j.revmed.2011.03.005. Epub 2011 Apr 13.

Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before

Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P.

Expert Opin Investig Drugs. 2011 Sep;20(9):1243-61. doi: 10.1517/13543784.2011.601740. Epub 2011 Aug 2.

ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic

Hopkins CR.

ACS Chem Neurosci. 2011 Jun 15;2(6):279-80. doi: 10.1021/cn2000469.

Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders - contemporary approaches

Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME, Gąsiorowski K, Leszek J, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):175-83. doi: 10.2174/187152711794480410.

Intranasal insulin as a therapeutic option in the treatment of cognitive impairments

Benedict C, Frey WH 2nd, Schiöth HB, Schultes B, Born J, Hallschmid M.

Exp Gerontol. 2011 Feb-Mar;46(2-3):112-5. doi: 10.1016/j.exger.2010.08.026. Epub 2010 Sep 16.

Neurotherapeutic applications of nanoparticles in Alzheimer's disease

Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C.

J Control Release. 2011 Jun 10;152(2):208-31. doi: 10.1016/j.jconrel.2010.11.033. Epub 2010 Dec 4.

Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond

Decker M.

Curr Med Chem. 2011;18(10):1464-75. doi: 10.2174/092986711795328355.

Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese

Yang YH, Wu SL, Chou MC, Lai CL, Chen SH, Liu CK.

J Alzheimers Dis. 2011;23(3):391-7. doi: 10.3233/JAD-2010-100936.

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial

Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B.

J Alzheimers Dis. 2011;26(2):211-20. doi: 10.3233/JAD-2011-110134.

[Cytoskeletal alterations in Alzheimer's disease: the "skeleton" of therapeutic hope?]

Fodor KE, Pákáski M, Santha P, Janka Z, Kálmán J.

Neuropsychopharmacol Hung. 2011 Sep;13(3):163-71. doi: 10.5706/nph201109005.

A comprehensive strategy for dementia from primary prevention to end-stage management

Arai H.

Psychogeriatrics. 2011 Sep;11(3):131-4. doi: 10.1111/j.1479-8301.2011.00379.x.